In Q1'26, Pfizer's ROE stands at 2.98%, ROA at 1.29%, and ROIC at 1.94%, reflecting a modest positive performance across all metrics following a challenging Q4'25 where ROE and ROA dipped into negative territory at -1.91% and -0.79%, respectively, while ROIC data is unavailable for that period. Over the period from Q2'23 to Q1'26, the metrics exhibit volatility with an overall stabilizing trend toward positive values; ROE and ROA fluctuated between highs of 4.84% (ROE in Q3'24) and lows of -3.78% (ROE in Q4'23), showing recovery patterns in 2024 and 2025 except for the Q4'25 downturn, whereas ROIC experienced a sharp anomaly at -132.68% in Q4'24 amid otherwise consistent single-digit positives, with data gaps in Q2'25 and Q4'25 limiting full trend visibility.